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and Shigeyoshi Kumeda1Abstract
A case of synchronous carcinoma of the accessory mammary gland and primary breast lymphoma with subsequent
rectal carcinoma has not been reported previously. We present a very rare case of primary non-Hodgkin lymphoma
of the left breast diagnosed simultaneously with invasive lobular carcinoma of the left axillary accessory mammary
gland and rectal adenocarcinoma. An 82-year-old Japanese woman presented with two palpable masses on the left
chest wall. She was given a diagnosis of suspected breast malignant tumor and axillary accessory mammary gland.
She underwent excision of the axillary accessory mammary gland and left mastectomy with axillary lymph node
dissection. Histopathological examination revealed diffuse large B-cell lymphoma of the breast and invasive lobular
carcinoma of the axillary accessory mammary gland with lymph nodes metastasis. Three months after the surgery,
primary rectal adenocarcinoma was also detected by F-18 fluorodeoxyglucose positron emission tomography.
Hartmann’s operation was performed, since which time the patient has been doing well.
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The synchronous occurrence of multiple neoplastic pro-
cesses is uncommon, and coexistence with cancer and
lymphoproliferative diseases of the breast is also unusual
[1]. Furthermore, a carcinoma arising in the accessory
mammary gland is rare, especially of the invasive lobular
type [2]. We present an extremely rare case of synchron-
ous primary non-Hodgkin lymphoma (NHL) of the left
breast with invasive lobular carcinoma of the ipsilateral
axillary accessory mammary gland, with subsequent rec-
tal adenocarcinoma.
Case presentation
An 82-year-old Japanese woman was referred to our
hospital with two left breast masses. She had no previous* Correspondence: nkoide@shinshu-u.ac.jp
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unless otherwise stated.breast problems or a family history of breast cancer. She
had a history of persistent hepatitis C virus (HCV) infec-
tion, Alzheimer-type dementia, and left femoral neck
fracture. No previous fever, night sweats, or weight loss
was reported.
Physical examination revealed two masses on the left
chest wall. One was a 3 × 3 cm, firm, freely mobile, and
indolent mass in the upper outer quadrant of the left
breast. The other was a 2 × 1 cm, elastic, and freely mo-
bile mass in the lower part of the left axilla. The axillary
mass was completely separate from the breast. Labora-
tory studies showed an increased soluble interleukin-2
receptor level of 547 U/ml, carcinoembryonic antigen of
5.4 ng/ml, and antibody to HCV (anti-HCV) with signal-
to-cut-off ratio of 12.77. Mammography demonstrated a
round, high-density, circumscribed mass, without micro-
calcification and spicula. Ultrasonographic examination of
the breast tumor revealed an oval, hypoechoic, heteroge-
neous lesion, without posterior acoustic phenomena. Sinceral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vealed that it could be categorized as being suspected of
malignancy, left mastectomy with axillary lymph node dis-
section and excision of the axillary accessory mammary
gland were performed.Figure 1 Microscopic examination of the breast tumor. (A) Atypical lym
(hematoxylin and eosin stain, original magnification × 4). (B) Cytokeratin sta
immunostain, original magnification × 4). (C) The neoplastic cells have a lar
(hematoxylin and eosin stain, original magnification × 40). (D) The cells areGross examination of the breast mass revealed a white,
firm tumor measuring 2.5 × 1.5 cm. Microscopic exam-
ination revealed diffuse sheet-like proliferation of atyp-
ical lymphocytes (Figure 1). The neoplastic cells were
large with irregular nuclei containing prominent nucleoliphoid cells have infiltrated diffusely into the mammary glands
in enhances mammary ducts (arrowheads) (cytokeratin AE1/AE3
ge nucleus containing prominent nucleoli and vesicular chromatin
positive for CD20 (CD20 immunostain, original magnification × 20).
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identified. On immunohistochemistry, the neoplastic
cells were positive for CD20 and MUM1, and negative
for CD3, CD5, CD10, and Bcl-6. These results confirmed
the diagnosis of diffuse large B-cell lymphoma (DLBCL),Figure 2 Microscopic examination of the accessory mammary gland.
(arrowhead) (hematoxylin and eosin stain, original magnification × 10). (B)
The mammary duct is adjacent to the cancer cells (arrowhead) (cytokeratin
cells have pale to slightly eosinophilic cytoplasm and a nucleus with pale c
(D) The cancer cells are negative for E-cadherin (E-cadherin immunostain, onot otherwise specified, and non-germinal center B-cell-
like type. On the other hand, histopathology of the axil-
lary tumor revealed ductal structures, fibrous tissue, fat
tissue, and infiltrating cancer cells (Figure 2). The cancer
cells showed dispersed or trabecular infiltrating growth(A) The cancer cells have infiltrated around a mammary duct
Cytokeratin stain enhances the cancer cells and the mammary duct.
AE1/AE3 immunostain, original magnification × 10). (C) The cancer
hromatin (hematoxylin and eosin stain, original magnification × 20).
riginal magnification × 20).
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consisted of pale to slightly eosinophilic cytoplasm and a
round nucleus with pale chromatin. On immunohisto-
chemistry, the cancer cells were positive for cytokeratin
AE1/AE3 and negative for E-cadherin. Furthermore, they
exhibited a positive reaction to anti-estrogen receptor
and anti-progesterone receptor, but were negative for
HER2. These findings were consistent with invasive
lobular carcinoma. All dissected lymph nodes were posi-
tive for metastatic lobular carcinoma.
The patient underwent only adjuvant hormonal therapy
with anastrozole at a dose of 0.79 mg/m2/day. F-18 fluoro-
deoxyglucose positron emission tomography 3 months
after the surgery showed no evidence of distant metastasis
of the carcinoma or infiltration of the lymphoma; how-
ever, it revealed focal accumulation in the lower rectum.
Colonoscopy demonstrated a rectal carcinoma forming
a fungating tumor with central ulceration. Hartmann’s
operation was performed. The pathological findings
revealed well- to moderately differentiated adenocarcin-
oma invading through the muscularis propria (Figure 3).
There has been no recurrence or distant metastasis in
the 7 months of follow-up since the last surgery.
Discussion
Primary breast lymphoma (PBL) is a rare disease, ac-
counting for 0.05% to 0.53% of all malignant breast tu-
mors, 0.38% to 0.7% of all lymphomas, and 1.7% to 2.2%Figure 3 Surgical specimen and microscopic examination of the recta
measuring 15 × 15 mm. (B) Microscopic examination shows an adenocarcin
shows infiltrating growth in the muscularis propria (hematoxylin and eosinof all extranodal lymphomas [3-5]. The majority of cases
are NHL and the most common histological subtype is
DLBCL (40% to 70% of all PBLs) [6]. Extranodal mar-
ginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma) is a distinct subgroup of PBL,
accounting for 8.5% to 35% of all PBLs [6]. The diagnos-
tic criteria for PBL proposed by Wiseman are the stand-
ard definition for this disease [7]. These criteria are: 1)
presence of technically adequate pathologic specimens,
2) close association of mammary tissue and lymphoma-
tous infiltrate, 3) no prior diagnosis of an extramammary
lymphoma, and 4) no evidence of concurrent widespread
disease, except for ipsilateral axillary lymph nodes if con-
comitant with the primary lesion.
The incidence of accessory mammary gland ranges
from 0.6% to 6% of women in various ethnic groups [8].
Accessory mammary gland tissue is vulnerable to the
same physiological and pathological changes, both be-
nign and malignant, as normal breast tissue [9]. Cancer
of the accessory mammary gland is a rare entity, ac-
counting for 0.3% to 0.6% of all breast cancer [8]. The
incidence of malignant change in the accessory mam-
mary gland is unclear because the true incidence of
accessory mammary gland is uncertain. The principal
malignancy identified in accessory mammary gland is
invasive ductal carcinoma (IDC) (79%), followed by
medullary and lobular carcinomas, which are seen in
less than 10% of cases [2]. Mitsuyoshi and colleaguesl carcinoma. (A) Surgical specimen showing that is a type 2 tumor
oma forms moderate- to large-sized atypical glands. The carcinoma
stain, original magnification × 4).













Relationship between PBL and
carcinoma
Remarks
1 [11] 49/F Diffuse, mixed cell type, B-cell type Left IDC 50 × 45/unknown (not
palpable)
Absent Contralateral -
2 [1] 62/F B-cell NHL, diffuse high grade Right IDC 28/9 Absent Contralateral *
3 [12] 62/F DLBCL Right IDC 29 × 28/13 × 10 Absent Ipsilateral -
4 [13] 53/F MALT lymphoma Left IDC 25/25 PBL Ipsilateral, colliding with each
other
-
5 [14] 57/F MALT lymphoma Right IDC + DCIS Unknown (palpable)/8 right
+ 12 left
PBL Ipsilateral, both in the same
quadrant
-
6 [15] 47/F B-cell NHL Right IDC 50 × 40 × 40/50 × 40 × 40 Absent Ipsilateral, adjacent to each other -
7 [16] 79/F Large B-cell lymphoma of follicular
cell origin
Bilateral IDC Both unknown (palpable) Absent Ipsilateral distance: 9 mm †
8 [17] 66/F DLBCL Right DCIS 20/unknown (palpable) Absent Ipsilateral distance: within 2 cm -
Present case 82/F DLBCL Left ILC 25 × 15/17 × 7 Carcinoma Ipsilateral ‡
*Synchronous triple tumors, with bilateral Brenner tumors of the ovary. †Mouse mammary tumor virus sequences were identified. ‡The carcinoma occurred from the accessory mammary gland and posterior rectal
cancer was diagnosed. DCIS, ductal carcinoma in situ; DLBCL, diffuse large B-cell lymphoma; F, female; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MALT, mucosa-associated lymphoid tissue; NHL,
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must be pathologically demonstrated to be adjacent to
normal breast parenchyma that is not connected with
normally positioned breast, and it is also necessary to
rule out the possibility of a metastatic lesion from an-
other primary cancer [10].
The synchronous occurrence of a carcinoma of the
accessory mammary gland and PBL is an extremely rare
finding, especially with a rectal carcinoma. To the best of
our knowledge, this combination of synchronous double
primary malignancies and rectal carcinoma has not been
reported previously. We believe that this is the first re-
ported case of its kind.
There have been only eight cases of the coincidence of
breast cancer and PBL (excluding cases that did not sat-
isfy Wiseman’s criteria for PBL, such as those with bone
marrow infiltration); therefore, these are also rare en-
tities [1,11-17]. Herein, we summarize reported cases of
synchronous double malignancies, along with our case
(Table 1). The ages of the patients varied from 47 to
82 years of age, and the mean age was 61.9 years. Hist-
ology of PBL was B-cell NHL in all cases, and the major
histological subtype was DLBCL (three cases). The ma-
jority of carcinomas were IDC, and only our case was in-
vasive lobular carcinoma. Two neoplasms occurred
ipsilaterally in seven cases, and in four cases the two tu-
mors were close, within 2 cm of each other. In particu-
lar, in Case 4, the two tumors were invading each other
and presenting as a “collision tumor”. Both Susnik and
colleagues [18] and Anavekar and colleagues [19] re-
ported cases of concurrent breast MALT lymphoma with
bone marrow infiltration and ipsilateral breast cancer,
respectively. Interestingly, the case of Susnik and col-
leagues exhibited a collision tumor like Case 4. In cases
with the coincidence of primary or secondary breast
lymphoma and breast cancer, MALT lymphoma may
occur more frequently than expected.
In Case 7, mouse mammary tumor virus (MMTV) se-
quences were detected by PCR of samples taken from IDC.
MMTV has long been postulated as a causative agent of
human breast cancer [20]. However, this remains contro-
versial [20,21]. Salmons and Gunzburg reviewed some re-
cent reports in 2013 [21], and they did not accept the
association with MMTV and human breast cancer, but
suggested that it could be worthwhile to revisit these earl-
ier studies. We did not attempt to detect MMTV se-
quences in our case.
There is also a possibility that HCV has been associ-
ated with B-lymphocyte proliferative disorders as well as
various extrahepatic diseases [22]. On the strength of
epidemiological data, emerging biological investigations,
and clinical observations, Viswanatha and Dogan sum-
marized and concluded that HCV was involved in the
pathogenesis of at least a proportion of patients withNHL [23]. Okan and colleagues found that the anti-
HCV seropositivity rate was significantly higher in the
DLBCL subgroup (4 of 67 cases) than in the controls (9
of 802 cases) [24]. In our case, anti-HCV was examined
four times in 1 year before and after admission, and all
of the signal-to-cut-off ratios were about 10 and consist-
ently high. This result suggests that the patient had had
HCV infection before admission. There was a non-zero
possibility that persistent HCV infection led to occur-
rence of the lymphoma.
Susnik and colleagues suggested that the coexistent
carcinoma acted as an antigenic stimulant, which may
have triggered the lymphomagenesis, a mechanism simi-
lar to the pathogenesis of acquired MALT lymphoma of
the stomach as a result of the reaction to infection with
Helicobacter pylori [18]. Since breast lymphoma usually
grows rapidly [25], this suggestion is reasonable. By con-
trast, Broco and colleagues reported that ipsilateral IDC
developed 1 year after an excision biopsy and conserva-
tive therapy of PBL, so prior lymphoma might also con-
tribute to carcinogenesis [26]. From the above findings,
both prior breast cancer and lymphoma may be possible
causes of synchronous malignancy.
Conclusion
We report an extremely rare case of synchronous ipsilat-
eral carcinoma of the accessory mammary gland and
PBL, with subsequent rectal carcinoma.
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